Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19
© 2020 The British Pharmacological Society..
It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 87(2021), 3 vom: 02. März, Seite 1547-1553 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Batteux, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.03.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.14489 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31268715X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31268715X | ||
| 003 | DE-627 | ||
| 005 | 20231225144941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14489 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM31268715X | ||
| 035 | |a (NLM)32692462 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Batteux, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The British Pharmacological Society. | ||
| 520 | |a It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adverse drug reactions | |
| 650 | 4 | |a antiretroviral drug | |
| 650 | 4 | |a hepatotoxicity | |
| 650 | 4 | |a pharmacovigilance | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Prothrombin |2 NLM | |
| 650 | 7 | |a 9001-26-7 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Bodeau, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gras-Champel, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Liabeuf, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Lanoix, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Schmit, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Andréjak, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbib, Yoann |e verfasserin |4 aut | |
| 700 | 1 | |a Haye, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Masmoudi, Kamel |e verfasserin |4 aut | |
| 700 | 1 | |a Lemaire-Hurtel, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bennis, Youssef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 87(2021), 3 vom: 02. März, Seite 1547-1553 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g number:3 |g day:02 |g month:03 |g pages:1547-1553 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14489 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2021 |e 3 |b 02 |c 03 |h 1547-1553 | ||